Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3 clinical study titled A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy. The study aims to assess the safety and efficacy of upadacitinib in treating moderate to severe hidradenitis suppurativa (HS) in patients who have not responded to anti-TNF therapy. This research is significant as it could offer a new treatment option for HS, a painful inflammatory skin condition.
The intervention being tested is upadacitinib, an oral tablet already approved for several inflammatory conditions like ulcerative colitis and rheumatoid arthritis. It is being evaluated for its potential to treat HS by reducing disease activity and managing adverse events.
The study design is interventional, with participants randomly assigned to different treatment groups. It employs a parallel intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on June 21, 2023, with primary completion expected in 2025, and the last update was submitted on July 7, 2025. These dates are crucial as they mark the progression and anticipated milestones of the study.
From a market perspective, positive outcomes from this study could enhance AbbVie’s stock performance by expanding the use of upadacitinib into a new therapeutic area. This could also influence investor sentiment positively, especially as the company competes in the competitive field of inflammatory disease treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.